BioSpace News Archive

Adamas Pharmaceuticals, Inc. announced that the compensation committee of the company’s board of directors granted three new employees restricted stock units to acquire 22,500 shares of the company’s common stock.

Further to Health Canada’s statement on April 30, 2021 , Health Canada has completed its quality review of the shipment of Janssen vaccines that are currently in quarantine.

Keros Therapeutics today presented data from the ALK2 and KER-050 hematology programs at the European Hematology Association EHA2021 Virtual Congress held from June 9 through June 17, 2021.

atai Life Sciences B.V. today announced the commencement of a proposed underwritten initial public offering of 14,286,000 of its common shares.

ESO today announced findings from a peer-reviewed research study focused on prehospital ketamine.

Moderna, Inc. and Tabuk Pharmaceutical Manufacturing Company today announced an agreement to commercialize the Moderna COVID-19 Vaccine and future variant-specific booster candidates in Saudi Arabia.

Increasing use of bioresorbable polymers in medical sector, rising number of orthopedic surgeries performed across the globe, and advancements in orthopedic bioresorbable implants are some key factors driving market growth.

At the forefront of the fight against COVID-19, Integral Molecular’s rapid Epitope Mapping technology is being used to pinpoint precise binding sites of therapeutic SARS-CoV-2 antibodies under development and can help determine their effectiveness against emerging viral variants.

Marius Pharmaceuticals, a patient-centric healthcare company focusing on therapies designed for hypogonadism, more commonly known as testosterone deficiency, today announced the publication of a study on the effects of oral testosterone undecanoate KYZATREX™ on ambulatory blood pressure in hypogonadal men in The Journal of Clinical Hypertension.

CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the closing of the offering of 1,400,000 shares of its common stock at a price of $22.62 per share, for total gross proceeds of approximately $31.7 million, before deducting underwriting discounts and other offering expenses payable by the Company.